# US 2025/0367185 A1 · Translesion synthesis polymerase inhibitors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367185 A1
- Document ID: US20250367185A1
- Status: Published application
- Kind: A1
- Application number: 19/107,830
- Filed: 2023-08-31
- Published: 2025-12-04
- Earliest claimed: 2022-09-01
- Assignees: University of Vermont and State Agricultural College
- Applicants: The University of Vermont and State Agricultural College
- Inventors: Nimrat Chatterjee
- Web page: https://patentgrep.com/patent/US20250367185A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are compositions and methods relating to the inhibitors of the translesion synthesis (TLS) pathway, including methods of preventing or treating RNA viruses and prolonged symptoms (for example, long COVID).

## Claims

### Claim 1

A method of treating a viral infection in a subject, wherein the method comprises administering to the subject an inhibitor of the translesion synthesis (TLS) pathway.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inhibitor comprises an inhibitor of a mutagenic translesion synthesis polymerase.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mutagenic translesion synthesis polymerase is selected from the group consisting of: POLh, POLK, POLI, REV1, REV3L, and REV7.

### Claim 4 (depends on 3)

The method of claim 3, wherein the mutagenic translesion synthesis polymerase comprises REV1.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the inhibitor of a translesion synthesis polymerase comprises a small molecule inhibitor.

### Claim 6 (depends on 5)

The method of claim 5, wherein the small molecule inhibitor comprises Compound 1:

### Claim 7

The method of any one of the preceding claims, wherein the viral infection is caused by an RNA virus.

### Claim 8 (depends on 7)

The method of claim 7, wherein the RNA virus is selected from the group consisting of: coronavirus, Dengue virus, retrovirus, flavivirus, Nipah virus, West Nile virus, human papillomavirus, respiratory syncytial virus, filovirus, Zaire ebolavirus, Sudan ebolavirus, Marburg virus, and influenza virus.

### Claim 9 (depends on 8)

The method of claim 8, wherein the viral infection is coronavirus.

### Claim 10 (depends on 9)

The method of claim 9, wherein the coronavirus comprises a betacoronavirus.

### Claim 11 (depends on 10)

The method of claim 10, wherein the betacoronavirus comprises SARS-COV-2 or a variant thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the SARS-COV-2 variant is selected from the group consisting of: alpha, beta, gamma, delta, omicron BA-1, omicron BA-2, omicron BA.4, omicron BA.5, XBB.1.5, XBB.1.16, and EG.5.

### Claim 13 (depends on 11)

The method of claim 11, wherein the variant comprises a circulating SARS-COV-2 variant.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject has, or is suspected of having, long COVID.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject is human.

### Claim 16 (depends on 15)

The method in claim 15, wherein the subject has at least one of: cardiomyopathy, neurological issues, diabetes, respiratory system disorders, nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, gastrointestinal disorders, musculoskeletal pain, anemia, headaches, shortness of breath, anosmia, parosmia, muscle weakness, and low fever.

### Claim 17

The method of any of the preceding claims, wherein the subject is administered the inhibitor by oral administration or intravenous administration.

### Claim 18

A pharmaceutical composition suitable for treating a viral infection in a subject, wherein the pharmaceutical composition comprises an inhibitor of the translesion synthesis (TLS) pathway.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

### Claim 20 (depends on 18, 19)

The pharmaceutical composition of any one of claims 18-19, wherein the inhibitor of the TLS pathway comprises an inhibitor of a mutagenic translesion synthesis polymerase.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the mutagenic translesion synthesis polymerase is selected from the group consisting of: POLh, POLK, POLi, REV1, or REV7.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the mutagenic translesion synthesis polymerase comprises REV1.

### Claim 23 (depends on 18, 19, 20, 21, 22)

The composition of any one of claims 18-22, wherein the inhibitor of the TLS pathway comprises a small molecule inhibitor.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein the small molecule inhibitor comprises Compound 1.

### Claim 25 (depends on 18, 19, 20, 21, 22, 23, 24)

The pharmaceutical composition of any one of claims 18-24, wherein the viral infection is caused by an RNA virus.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the RNA virus is selected from the group consisting of: coronavirus, Dengue virus, retrovirus, flavivirus, Nipah virus, West Nile virus, human papillomavirus, respiratory syncytial virus, filovirus, Zaire ebolavirus, Sudan ebolavirus, Marburg virus, and influenza virus.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26, wherein the virus is a coronavirus.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein the coronavirus is a betacoronavirus.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein the betacoronavirus comprises SARS-COV-2 or a variant thereof.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the SARS-COV-2 variant is selected from the group consisting of: alpha, beta, gamma, delta, omicron BA-1, omicron BA-2, omicron BA.4, omicron BA.5, XBB.1.5, XBB.1.16, and EG.5.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein the variant comprises a circulating SARS-COV-2 variant.

### Claim 32 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The pharmaceutical composition of any one of claims 18-31, wherein the subject has or is suspected of having long-COVID.

### Claim 33 (depends on 32)

The pharmaceutical composition of claim 32, wherein the subject is human.

### Claim 34

The pharmaceutical composition of 33, wherein the subject has at least one of: cardiomyopathy, neurological issues, diabetes, aging, respiratory system disorders, nervous system and neurocognitive disorders, mental health disorders, metabolic disorders, gastrointestinal disorders, musculoskeletal pain, anemia, headaches, shortness of breath, anosmia, parosmia, muscle weakness, and low fever.

### Claim 35 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The pharmaceutical composition of any one of claims 18-34, wherein the pharmaceutical composition is administered by oral administration or intravenous administration.

### Claim 36 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The pharmaceutical composition of any one of claims 18-35, wherein the pharmaceutical composition is formulated as a capsule.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical composition is acceptable for oral administration.

### Claim 38 (depends on 34, 35, 36, 37)

The pharmaceutical composition of any of claims 34-37, wherein the pharmaceutical composition is administered according to a dosing schedule sufficient to alleviate at least one symptom.
